Every material Form 8-K PTC Therapeutics filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PTC Therapeutics' Board of Directors authorized a share repurchase program allowing the company to buy back up to $500 million of its common stock, subject to market conditions. The filing does not give a timing or schedule for purchases, and the company says repurchases will be made at management's discretion and reported in its Form 10-Q and Form 10-K filings.
Authorization: up to $500 million of outstanding common stock, announced November 3, 2026
Repurchases may be made from time to time at management's discretion, subject to market conditions
Methods include open-market transactions with pre-set trading plans, privately negotiated deals, and accelerated share repurchases
CEO Matthew B. Klein said the program leaves financial flexibility to support existing programs and pursue potential business development transactions
PTC Therapeutics reported third-quarter 2026 total revenue of $358 million, up from $211.0 million a year earlier, and raised its full-year 2026 total and product revenue guidance. The company also recorded a net loss of $51.7 million, compared with net income of $15.9 million in the prior-year quarter, after a $111.0 million acquired in-process R&D charge for the ST-920 Fabry gene therapy.
Q3 2026 total revenue was $357.8 million, versus $211.0 million in Q3 2025; Sephience net product revenue was $181.9 million.
Net loss was $51.7 million ($0.62 per share) versus net income of $15.9 million a year earlier, including the $111.0 million ST-920 charge.
Full-year 2026 product revenue guidance was raised to $960 to $990 million from $850 to $950 million; total revenue guidance is $1.29 to $1.32 billion.
Cash, cash equivalents and marketable securities were $2,127.9 million on September 30, 2026.
PTC Therapeutics entered an asset purchase agreement on August 25, 2026 to acquire ST-920, an AAV gene therapy candidate for Fabry disease, from bankrupt Sangamo Therapeutics. The deal carries a $111 million upfront payment plus up to $100 million in contingent milestones tied to FDA approval, and closing requires Bankruptcy Court approval, which is scheduled for a hearing on September 10, 2026.
Upfront payment of $111 million, plus up to $100 million in contingent milestones ($80 million on accelerated approval and $20 million on full approval)
Acquisition is subject to Bankruptcy Court approval (hearing scheduled September 10, 2026) and Hart-Scott-Rodino waiting period expiration
Either party may terminate if closing has not occurred by October 15, 2026, subject to specified exceptions
Representations and warranties do not survive closing and there is no indemnification for breaches
PTC Therapeutics reported second-quarter 2026 total revenue of $360.5 million, up from $178.9 million a year earlier, and net income of $83.5 million, compared with a net loss of $64.8 million in the prior-year quarter. The company raised its 2026 product revenue guidance to $850 million to $950 million and its total revenue guidance to $1.18 billion to $1.28 billion, and it also appointed Hege Sollie-Zetlmayer, its former Chief Human Resources Officer, to the board.
Q2 2026 total revenue was $360.5 million, including $238.8 million of net product revenue and a $50.0 million Novartis milestone recorded as collaboration revenue.
Full-year 2026 product revenue guidance was raised to $850 million to $950 million from $750 million to $850 million.
Sephience generated $151.3 million in Q2 2026 net product revenue; cash, cash equivalents and marketable securities were $2.2 billion as of June 30, 2026.
Hege Sollie-Zetlmayer was appointed to the board effective July 28, 2026, filling a vacancy.
PTC Therapeutics completed a private offering of $550 million in 0.0% convertible senior notes due June 15, 2031, including the full $50 million option exercised by the initial purchasers. The company is using about $328.8 million of the estimated $535.5 million net proceeds to repurchase $222.0 million of its existing 1.50% convertible notes due 2026, leaving $55.5 million of those notes outstanding, which shifts its debt toward the new notes for shareholders.
Notes: $550 million principal, 0.0% interest, maturing June 15, 2031
Initial conversion price of approximately $107.48 per share (9.3042 shares per $1,000 principal)
Estimated net proceeds of $535.5 million; $328.8 million used to repurchase $222.0 million of 2026 notes
Existing 1.50% convertible notes outstanding after repurchases: $55.5 million
PTC Therapeutics director Alethia Young resigned from the board effective June 8, 2026, citing commitments to other work activities and not any disagreement with the company. She will remain as an advisor under a consulting agreement running through June 8, 2027, for a monthly fee of $4,166.67.
Alethia Young resigned from the board of directors effective June 8, 2026.
Resignation was stated to be due to her need to focus on other work commitments, not a disagreement with the company.
Consulting agreement runs June 8, 2026 through June 8, 2027, at $4,166.67 per month (Exhibit 10.1).
PTC Therapeutics reported first quarter 2026 total revenue of $272.6 million and a net loss of $2.8 million, or $0.03 per share, compared with net income of $866.6 million a year earlier. The year-earlier figure included $986.2 million of collaboration and license revenue, while net product revenue rose 47% to $225.6 million. The company raised its full-year 2026 product revenue guidance to $750 million to $850 million.
Total revenue was $272.6 million in Q1 2026, versus $1,176.1 million in Q1 2025, which included $986.2 million of collaboration and license revenue.
Net product revenue was $225.6 million, up 47% from $153.4 million a year earlier; Sephience revenue was $124.6 million.
Net loss was $2.8 million, or $0.03 per share, compared with net income of $866.6 million in Q1 2025.
Full-year 2026 total product revenue guidance was raised to $750 million to $850 million, with expected total revenue of $1.08 billion to $1.18 billion; GAAP R&D and SG&A expense guidance was unchanged at $775 million to $815 million.
PTC Therapeutics appointed Jessica Chutter to its board of directors effective March 24, 2026, filling a vacancy as a Class I director. Ms. Chutter retired from Morgan Stanley in February 2026 after more than 40 years in healthcare investment banking, and she received standard outside director pay and equity grants.
Appointed March 24, 2026, as a Class I director with a term expiring at the 2026 annual meeting
Receives a $50,000 base annual retainer under the outside director compensation policy
Initial grant of 3,475 stock options and 4,000 restricted stock units, plus a pro-rated 2026 annual grant of 2,896 options and 3,333 RSUs
Previously Managing Director and Chair of Biotechnology Investment Banking at Morgan Stanley; company says she was involved in about $80 billion of capital raising and $85 billion of strategic transactions
PTC Therapeutics reported fourth-quarter 2025 total revenue of $164.7 million, down from $213.2 million a year earlier, and a net loss of $135.0 million, wider than the $65.9 million loss in the prior-year quarter. For the full year, total revenue rose to $1,730.7 million and net income was $682.6 million, but both figures were lifted by a $998.4 million Novartis votoplam collaboration and license revenue item. The company also issued 2026 total product revenue guidance of $700 million to $800 million.
Q4 2025 total revenue was $164.7 million versus $213.2 million in Q4 2024; Q4 net loss was $135.0 million versus $65.9 million.
Q4 results include a $98.6 million change in the Translarna France sales allowance estimate, a life-to-date adjustment.
Full-year 2025 net income was $682.6 million, or $7.78 per diluted share, versus a net loss of $363.3 million in 2024.
2026 guidance: total product revenue of $700 million to $800 million, with the majority expected from Sephience.
PTC Therapeutics said preliminary, unaudited 2025 total product and royalty revenue was about $823.4 million, which it describes as exceeding its guidance. The company also guided to 2026 total product revenue of $700 million to $800 million, excluding Evrysdi royalty and collaboration revenue, and to GAAP R&D and SG&A expense of $775 million to $815 million. Final 2025 results remain subject to the year-end audit.
Unaudited 2025 total product and royalty revenue of about $823.4 million; unaudited total product revenue of about $587.8 million
Sephience unaudited Q4 2025 net revenue of about $92.5 million, including $81.6 million in the US and $10.9 million ex-US
2026 guidance: total product revenue of $700 million to $800 million, excluding Evrysdi royalty and collaboration revenue
2026 GAAP R&D and SG&A expense guidance of $775 million to $815 million, or $680 million to $720 million excluding about $95 million of non-cash stock-based compensation
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PTC Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →